Instead, we applied a previously published model of HHT, based on administration of BMP9 and BMP10 blocking antibodies (bAbs), to provoke AVMs within the developing retinal vasculature [11, 12]. The gene discussed is GDF2; the disease is hereditary hemorrhagic telangiectasia.